Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | GSK3B | P49841 | 6/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17633410 | 0.87 | ROCK2 (0.44) | ROCK2GPR119GSK3BPTPN1USP30 | |
| SCHEMBL2426228 | 0.84 | ROCK2 (0.56) | ROCK2GPR119USP30SCDMKNK1 | |
| SCHEMBL3087005 | 0.83 | ROCK2 (0.60) | ROCK2GPR119GSK3BPTPN1USP30 | |
| SCHEMBL13267260 | 0.82 | ROCK2 (0.54) | ROCK2GPR119USP30SCD | |
| SCHEMBL15742917 | 0.80 | ROCK2 (0.60) | ROCK2GPR119GSK3BPTPN1USP30 | |
| SCHEMBL13144317 | 0.80 | ROCK2 (0.57) | ROCK2GPR119GSK3BPTPN1USP30 | |
| SCHEMBL25445548 | 0.80 | ROCK2 (0.56) | ROCK2GPR119USP30SCD | |
| SCHEMBL22042387 | 0.78 | ROCK2 (0.55) | ROCK2GPR119GSK3BPTPN1USP30 | |
| SCHEMBL15742834 | 0.76 | ROCK2 (0.53) | ROCK2GPR119USP30SCD | |
| SCHEMBL23615970 | 0.76 | ROCK2 (0.53) | ROCK2GPR119GSK3BPTPN1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956013-B1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8022075-B2 | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition | FUJIFILM RI PHARMA CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090162283-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO., LTD. (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-1956013-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | Fujifilm RI Pharma Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162283-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | APP, TTR, BACE1 | ROCK2 4645/4885GPR119 2805/4885GSK3B 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.